Abstract
Today, with an increasing medicolegal environment, therapeutic drug monitoring (TDM) has become more essential. The concentration of HPD in the serum is an effective way to safely monitor the clinical use of HPD. Markit-M Haloperidol, an enzyme-immunoassay, was developed as an assay method of HPD in the serum to have a simpler and quicker procedure with a higher sensitivity than the other previous HPD assay, the property of which was studied in the reproducibility test, the recovery test, the dilution test and the specificity test as well as in the correlation to compare with Markit Haloperidol which is the former enzyme immunoassay. Five mg of HPD (i.v.) was injected into schizophrenic patients and followed by a time course of HPD serum concentration; a high correlation (corrective coefficient: r = 0.965) was found bwtween the 2 assays. Other basic examinations showed good results, including high specificity. Its higher sensitivity, speed and simplicity make this new assay advantageous as well as easily applicable and available for HPD drug therapy monitoring.
| Original language | English |
|---|---|
| Pages (from-to) | 233-239 |
| Number of pages | 7 |
| Journal | Japanese Journal of Neuropsychopharmacology |
| Volume | 16 |
| Issue number | 4 |
| Publication status | Published - May 11 1994 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Clinical Psychology
- Pharmacology
- Psychiatry and Mental health
- Pharmacology (medical)
Cite this
Determination of haloperidol in serum by Markit-M Haloperidol and its clinical application. / Oguchi, E.; Kanba, S.; Watanabe, K.; Yagi, G.
In: Japanese Journal of Neuropsychopharmacology, Vol. 16, No. 4, 11.05.1994, p. 233-239.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Determination of haloperidol in serum by Markit-M Haloperidol and its clinical application
AU - Oguchi, E.
AU - Kanba, S.
AU - Watanabe, K.
AU - Yagi, G.
PY - 1994/5/11
Y1 - 1994/5/11
N2 - Today, with an increasing medicolegal environment, therapeutic drug monitoring (TDM) has become more essential. The concentration of HPD in the serum is an effective way to safely monitor the clinical use of HPD. Markit-M Haloperidol, an enzyme-immunoassay, was developed as an assay method of HPD in the serum to have a simpler and quicker procedure with a higher sensitivity than the other previous HPD assay, the property of which was studied in the reproducibility test, the recovery test, the dilution test and the specificity test as well as in the correlation to compare with Markit Haloperidol which is the former enzyme immunoassay. Five mg of HPD (i.v.) was injected into schizophrenic patients and followed by a time course of HPD serum concentration; a high correlation (corrective coefficient: r = 0.965) was found bwtween the 2 assays. Other basic examinations showed good results, including high specificity. Its higher sensitivity, speed and simplicity make this new assay advantageous as well as easily applicable and available for HPD drug therapy monitoring.
AB - Today, with an increasing medicolegal environment, therapeutic drug monitoring (TDM) has become more essential. The concentration of HPD in the serum is an effective way to safely monitor the clinical use of HPD. Markit-M Haloperidol, an enzyme-immunoassay, was developed as an assay method of HPD in the serum to have a simpler and quicker procedure with a higher sensitivity than the other previous HPD assay, the property of which was studied in the reproducibility test, the recovery test, the dilution test and the specificity test as well as in the correlation to compare with Markit Haloperidol which is the former enzyme immunoassay. Five mg of HPD (i.v.) was injected into schizophrenic patients and followed by a time course of HPD serum concentration; a high correlation (corrective coefficient: r = 0.965) was found bwtween the 2 assays. Other basic examinations showed good results, including high specificity. Its higher sensitivity, speed and simplicity make this new assay advantageous as well as easily applicable and available for HPD drug therapy monitoring.
UR - http://www.scopus.com/inward/record.url?scp=0028288546&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028288546&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0028288546
VL - 16
SP - 233
EP - 239
JO - Japanese Journal of Neuropsychopharmacology
JF - Japanese Journal of Neuropsychopharmacology
SN - 1340-2544
IS - 4
ER -